Raj Bawa, MS, PhD, MD '22, is president of Bawa Biotech LLC (founded in 2002), a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia, USA. Trained as a microbiologist and biochemist, he is an inventor, entrepreneur, professor, and registered patent agent (since 2002) licensed to practice before the US Patent & Trademark Office. He is currently a scientific advisor to Teva Pharmaceutical Industries Ltd. (Israel), a visiting research scholar at the Pharmaceutical Research Institute of Albany College of Pharmacy (Albany, NY), and vice president/chief IP officer at Guanine, Inc. (Rensselaer, NY). He is also a medical student and will receive the MD degree in 2022. He has served as a principal investigator of various research grants, most recently as a principal investigator of a CDC grant to develop an assay for carbapenemase-resistant bacteria. He was an adjunct professor at Rensselaer Polytechnic Institute (Troy, NY) from 1998 to 2018, where he received his doctoral degree in three years (biophysics/biochemistry). In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office (Washington, DC), including primary examiner from 1996-2002. Presently, he is a life member of Sigma Xi, co-chair of the nanotech and precision medicine committees of the American Bar Association, and founding director of the American Society for Nanomedicine (founded in 2008). He has authored over 100 publications, co-edited 8 texts, and serves on the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of Nanomedicine (Elsevier). Some of Dr. Bawa's awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK; Appreciation Award from the Undersecretary of Commerce, Washington, DC; Key Award from Rensselaer's Office of Alumni Relations; and Lifetime Achievement Award from the American Society for Nanomedicine. Paul J. Davis, MD, is professor of medicine at Albany Medical College and adjunct professor of pharmacy at the Albany College of Pharmacy and Health Sciences, USA, He was selected as Top Endocrine Pharmacologist for 2018 by the International Association of Top Professionals (IAOTP) for his outstanding leadership and commitment to the profession. Dr. Davis directs a group of scientists who have defined molecular mechanisms for many nongenomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. They have described the cell surface receptor for thyroid hormone on integrin avb3 and the actions of tetraiodothyroacetic acid (tetrac) and reformulated (nanoparticulate) tetrac initiated at this plasma membrane receptor that are anti-angiogenic and anti-cancer by multiple cell surface and intracellular pathways. Jay K. Doshi, DDS, is president of Jay K. Doshi Dental Associates, PA, Spring, Texas, founded in 2009. He received his training from the University of Texas Houston dental branch. He has been in private practice since 2000. His practice caters to patients of all ages with an emphasis on preventative and all phases of cosmetic and restorative dentistry. He is a member of the American Dental Association, Texas Dental Association, and Greater Houston Dental Association. He also is a member of the prestigious Las Vegas Institute for Neuromuscular and Cosmetic Dentist. Mario Ganau, MD, PhD, MBA, is a neurosurgeon and scientist with a wide breadth of knowledge in the application of innovation technology to clinical practice. Following formal medical and neurosurgical training in Italy and France, he completed post-CCT fellowships in UK and Canada, before joining the Department of Neurosurgery at Oxford University Hospitals in 2018. His academic curriculum includes a PhD in nanotechnology and a PhD in biomedical engineering, as well as economics studies at Ecole Polytechnique Federale de Lausanne, Switzerland. Dr Ganau's core scientific interest focuses on the diagnostic and theranostic aspects of nanomedicine. Additionally, during his tenure as a visiting researcher at the Kennedy Institute of Ethics, Georgetown University, USA, he explored the ethical impact of those innovations with the aim to enhance the quality of a comprehensive technology-based patient-centered approach. During this path at the forefront of clinical practice and basic research, he authored over 100 peer-reviewed articles and book chapters and edited books, which led him to receive several awards, recognitions, and accolades in Europe, North America, and Asia.